The AgelessRx Peptide Standard: A Framework for Evaluating Compounded Peptide Programs

Executive Summary

Prepared by AgelessRx · Medically reviewed by Dr. Jenell Decker, MD · Last reviewed September 25, 2026 · Evidence reviewed through August 31, 2026 · Authorship and Review

What Makes a Peptide Product Trustworthy?

A trustworthy peptide program requires more than a purity test or a licensed pharmacy. It should provide verifiable sourcing, appropriate product-quality testing, evidence that supports the intended use, qualified clinical oversight, and a clear plan for patient monitoring.

The AgelessRx Peptide Standard evaluates these factors through two stages: Program Accountability and the PEPTIDE Decision Model.

See the Peptides Scorecard

Key Findings

Quick Answers to Common Peptide Questions

What Is the AgelessRx Peptide Standard?

Consumer interest in investigational peptides has outpaced the standards used to evaluate them. Most assessments today rely on a single signal: a purity percentage, a Certificate of Analysis, pharmacy licensure, or the existence of preclinical research. Each may provide useful information, but none is sufficient to establish the quality of a peptide program.

The AgelessRx Peptide Standard’s central objective is to establish an evaluation framework that assesses peptide programs across three distinct dimensions: a verifiable product, an evidence-calibrated claim, and an accountable system of clinical care. These are three different questions, and, most importantly for consumers, a peptide can pass one while failing another.

This paper introduces PEPTIDE, a single two-layer framework:

• The first layer, Program Accountability, assesses whether a provider or organization offering the peptide is trustworthy. This first layer serves as the initial gate.
• The second layer, the PEPTIDE Decision Model, is assessed per person, per peptide, per indication, and asks whether a specific use is a responsible decision. A program that fails Program Accountability is automatically designated as “not meeting the Standard,” regardless of how strong the individual evidence for a peptide looks.

The Peptide Standard was informed by FDA regulatory materials, analytical studies of falsified and consumer research-grade peptide products, peer-reviewed peptide literature, and established principles of evidence communication and clinical accountability. It is intended for consumers, clinicians, pharmacies, telehealth organizations, researchers, and journalists. It is not a clinical practice guideline, and it has not yet been externally validated. The full scoring rubric is included in the companion Clinician Scoring Toolkit (Part II); a consumer-facing scorecard applying the Standard to specific peptides is included in Part III.

The Peptide-Quality Problem: “Peptide” Does Not Describe a Level of Evidence

Two vials can carry the same peptide name while differing in ingredient source, manufacturing conditions, molecular identity, measured amount, purity, microbial quality, endotoxin burden, stability, dispensing pathway, clinical oversight, and the evidence supporting the protocol. The molecule on the label is only one part of the intervention; the complete intervention includes the product, the claims made about it, the patient-selection process, the dosing rationale, the monitoring plan, and the people accountable when something changes.

Regulatory Status Is Not Evidence Status

In July 2026, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) evaluated seven peptide-related bulk drug substances for potential inclusion on the Section 503A Bulks List and recommended six of them, all but emideltide. That recommendation did not make any of these peptides FDA-approved, and also did not add them to the Bulks List. The FDA describes advisory-committee recommendations as non-binding and stated in its own July briefing materials that the agency would not make its final determination until the advisory process and remaining reviews were complete.

A favorable regulatory recommendation does not establish effectiveness, strong clinical evidence does not establish lawful access through every pathway, a pure product is not automatically an appropriate treatment, and none of these factors independently determines whether a specific person should use a peptide.

See the Peptides Scorecard

How Are Compounded Peptides Legally Accessed? The 503A Pathway Explained

Section 503A of the Federal Food, Drug, and Cosmetic Act allows a state-licensed pharmacy or physician to compound a medication for an individual patient based on a valid prescription. A 503A pharmacy may only compound from a bulk drug substance that is a component of an FDA-approved drug, is the subject of a USP or NF monograph, or appears on the FDA’s 503A Bulk Drug Substances List (the “503A Bulks List”). Most peptides discussed in this Standard are not components of approved drugs and lack USP monographs, so the Bulks List is the pathway that determines whether they can be lawfully compounded at all.

That pathway is the specific regulatory basis that separates a clinically accessed compounded peptide from a gray-market “research use only” product. A 503A-compounded peptide is prescribed by a licensed clinician for a named patient, made from bulk ingredient sourced from an FDA-registered facility with a certificate of analysis, prepared under state pharmacy oversight and USP compounding standards, and dispensed through a traceable chain. A “research use only” vial sold online sits outside every one of those safeguards: it is labeled not for human use, is not dispensed against a prescription, and no licensed party is accountable for its identity, sterility, or dose once a person injects it.

An FDA advisory committee recommendation does not change that status on its own. PCAC recommendations are non-binding advice to the FDA; a favorable vote does not constitute FDA approval, does not add a substance to the 503A Bulks List, and does not by itself make a peptide available through compounding pharmacies. Only the FDA’s final determination does that, and even then a compounded peptide remains an unapproved drug whose safety and effectiveness the FDA has not reviewed for any indication. For a closer look at the gray-market side of this distinction, see what “research use only” actually means.

Methods and Scope

This paper uses a narrative evidence-synthesis approach. Sources reviewed included FDA meeting materials and compounding guidance, peer-reviewed analytical and pharmaceutical-quality research, primary and review literature on the peptides discussed, a 2026 preprint analyzing consumer research-grade peptide testing, and established principles of evidence classification and clinical monitoring, including GRADE, the Oxford CEBM levels, and the AAFP Strength-of-Recommendation Taxonomy.

This paper does not establish whether an individual peptide is appropriate for a particular patient. It is not a systematic review, meta-analysis, clinical practice guideline, or legal interpretation, and the scoring instruments described here have not undergone external validation, reliability testing, or prospective evaluation.

The AgelessRx PEPTIDE Standard: A Simple Two-Layer Framework

The AgelessRx Peptide Standard defines peptide quality across three interdependent dimensions.

These three dimensions show up at two points when considering a peptide use case and must be considered in sequence:

• Once when vetting the provider/organization (provider-level evaluation)
• Again when assessing a specific peptide’s evidence and current standing (peptide and patient-level evaluation)

Layer 1: Program Accountability (assessed once, for the provider or organization). Before asking whether a specific peptide makes sense for a specific person, there has to be confidence that the provider of that peptide, whether a clinician or telehealth company, the evidence claims, and the care model behind it can be trusted. This layer is scored across six domains: sourcing and traceability, analytical quality, clinical governance, evidence integrity, patient transparency, and outcomes accountability. The scoring rubric is as follows:

A program that does not meet the Standard is automatically disqualified from consideration. The full domain-by-domain scoring criteria (the original PQAI instrument) reside in Part II for anyone doing an actual organizational audit.

Layer 2: The PEPTIDE Decision Model (assessed per user, per peptide, per indication). This is the seven-pillar model that gives the Standard its name, allowing consumers to simply judge the individually available peptides based on the information that is currently available:

1. PPurity & provenanceWhere did this come from, and can we prove it is what it claims to be? (Informed by Program Accountability’s sourcing and analytical-quality domains)
2. EEvidence tierWhat does the evidence actually show for this peptide and this indication? (Informed by the evidence-integrity domain)
3. PPopulation fitWho should avoid it, or require a different level of monitoring?
4. TTiming & sequencingWhere does it belong relative to everything else in the care plan?
5. IIndication matchDoes the mechanism meaningfully map to the person’s biology or goal?
6. DDosing, delivery & diagnostic loopHow is it administered, monitored, and reassessed, and how is the patient guided throughout?
7. EExit & escalationWhat determines whether treatment continues, changes, or stops, and is that outcome tracked and reported?

Each pillar is translated into a PEPTIDE Suitability Score (0–10). Program Accountability and the Suitability Score are not two scores weighed against each other. Program Accountability is the gate; the Suitability Score is what you calculate once you’ve deemed that the provider of said peptide is trustworthy. Part II includes full pillar definitions, the score math, and an illustrative example of how to utilize this scoring system to evaluate a peptide and provider.

What the Available Quality Data Show

Quality failures take different forms. A 2018 forensic analysis of frequently encountered falsified polypeptide drugs on the Belgian market documented variable peptide content and, in some samples, impurities including heavy metals and residual solvents. A separate 2026 preprint evaluating thousands of consumer research-grade peptide samples found meaningful variability in measured abundance even where reported purity was relatively high.

These findings support a narrower but important conclusion: peptide quality cannot be established with one test, one percentage, or one document. The Standard begins with the system surrounding the peptide and then assesses whether a particular peptide makes sense for a particular person.

Applying the Standard, at a Glance

A complete assessment runs in the following order:

The full step-by-step process, with scoring criteria at each step, is in Part II.

We apply this Standard to our own program. Our current self-assessment, scored against the same domains we ask the rest of the field to meet, is published in Part II.

See the Peptides Scorecard

Illustrative Examples

BPC-157, Ulcerative Colitis / Tissue-Repair Use, Sourced Through a Licensed 503A Pharmacy With a Lot-Specific COA:

The FDA’s own review of BPC-157 for ulcerative colitis found the biological rationale and preclinical literature move the indication beyond speculative biology, but concluded the available evidence was insufficient to establish effectiveness, placing this use at Evidence Tier 3 (Investigational). Due to current restrictions on the legal compounding and prescription of BPC-157, it is disqualified as a research-use-only peptide. If the FDA adds BPC-157 to the 503A Bulks List, then, combined with verified sourcing and no population-fit contraindications, this profile lands in the Yellow zone: proceed only with enhanced informed consent and closer clinician monitoring, not as a routine, low-scrutiny prescription. The full scoring walkthrough, and nine more peptides scored the same way, are in Part III.

Sermorelin, Age-Related GH-Axis Support for Muscle Mass and Sleep, Sourced Through a Licensed Compounding Pharmacy With a Lot-Specific COA:

Sermorelin’s clinical history includes prior FDA approval for pediatric growth-hormone-deficiency use and a small body of controlled human research on supporting growth hormone levels in adults with growth hormone deficiency, as well as healthy adults. The evidence sits within a narrower population and indication than this broader adult-longevity use, placing this use at Evidence Tier 2 (Emerging). Because Sermorelin isn’t caught up in the current PCAC review affecting several other peptides on this scorecard, it clears today as a Verified peptide rather than a disqualified one; no reclassification is required. Combined with verified sourcing and no population-fit contraindications, this profile lands in the Green zone: reasonable to proceed with standard clinician monitoring, not the enhanced scrutiny a Yellow rating would require.

What the Standard Does Not Claim

A Tier 3 (Investigational) rating does not mean a peptide should be prescribed, and a favorable regulatory recommendation does not raise its Evidence Tier. A Tier 4 rating does not mean a peptide can never reach Tier 1; ratings move as evidence accumulates, an opportunity that may be present if the FDA approves inclusion on the Section 503A Bulks List. The purpose of grading is not to remove uncertainty but to make uncertainty visible and consistent across every peptide discussed.

Recommendations for the Field

(Recommendations addressed specifically to clinicians and consumers appear in Parts II and III.)

Layer 1: Program Accountability

Program Accountability answers one question: can the provider behind this peptide be trusted? It’s assessed once per provider or organization, not once per patient. It is scored across six domains, each worth 0–4 points, for a total of 24 possible points; each domain feeds one or more PEPTIDE pillars:

Scoring Principles

Each domain is scored as follows:

• 0: Absent or materially unacceptable
• 1: Minimal and substantially inadequate
• 2: Minimum standard met
• 3: Strong practice
• 4: Leading and independently verifiable practice

Most importantly, the score must be based on evidence, not an organization’s description of itself.

Essential domains: Sourcing & Traceability, Analytical Quality, and Clinical Governance. A program cannot meet the Standard if it scores below 2 in any essential domain, regardless of total score. This prevents strong marketing, education, or research activity from masking a fundamental product- or patient-safety gap.

Score Interpretation

Domain 1 — Sourcing & Traceability

Can the product be connected to an identifiable, accountable, licensed source?

Domain 2 — Analytical Quality

Is the finished preparation supported by testing appropriate to its identity, strength, formulation, and route?

Domain 3 — Clinical Governance

Is the peptide prescribed and monitored within an accountable clinical system?

Domain 4 — Evidence Integrity

Do the claims match the maturity and directness of the evidence?

Domain 5 — Patient Transparency

Can a patient understand what is known, unknown, expected, and required before deciding to participate?

Domain 6 — Outcomes Accountability

Does the organization systematically learn from use and contribute those findings to the field?

Layer 2: The PEPTIDE Decision Model

P — Purity & Provenance

The first question isn’t whether a peptide is promising, but whether the product can be trusted. This is inseparable from where it was made and how it was verified. USP General Chapter <797> (sterile compounding) and ASHP compounding guidelines are reasonable external benchmarks to ask a compounding pharmacy about directly.

E — Evidence Tier

This grading system is adapted from GRADE, the Oxford CEBM levels, and the AAFP Strength-of-Recommendation Taxonomy, but tailored to a category where many widely discussed peptides remain early in the evidence curve. It is designed for granular assessment of the evidence base, avoiding the tendency to collapse every peptide into a vague “moderate” middle.

P — Population Fit

Evidence describes groups while prescribing concerns individuals. Relevant factors include pregnancy/lactation, malignancy, renal or hepatic impairment, immune-related conditions, age, frailty, cardiometabolic disease, concurrent medications, and mechanism-specific risk factors. A high Evidence Tier and excellent sourcing cannot substitute for a serious patient-specific contraindication.

T — Timing & Sequencing

Responsible use asks, “Why this, why now?” Risk rises when a peptide is introduced too early, several interventions start at once, administration is inappropriate, or there’s no baseline to measure against.

I — Indication Match

Mechanism only matters when it maps to the problem being addressed. The rationale should be explicit enough to explain the mechanistic link clearly and specific enough to check against the evidence. This checkpoint guards against indication creep, where an interesting mechanism gradually becomes the justification for increasingly broad claims.

D — Dosing, Delivery & Diagnostics Loop

A responsible protocol defines route, formulation, individualized dose, titration where relevant, storage and handling, monitoring, and the measures used to evaluate response, as well as what the patient is told at each step (maps to Patient Transparency in the Program Accountability scoring system).

E — Exit & Escalation

Every protocol starts with an answer to a question that is often asked much too late: what would make us stop? Stopping criteria, reassessment timing, and escalation triggers should be set before treatment begins. The patient journey should be tracked and reported; this maps to Outcomes Accountability in the Program Accountability scoring system.

The PEPTIDE Suitability Score

A 10-point decision score. It is not an approval, a prescription recommendation, or a substitute for clinical judgment.

See the Peptides Scorecard

Applying the Standard, Step by Step

Applying the Standard to Ourselves

A standard is only meaningful if its authors are willing to be evaluated by it. We apply the same Program Accountability requirements to our own program that we propose for the rest of the category, scored on documented evidence rather than our own description of our practices.

Recommendations for Clinicians

The Peptide Standard at a Glance

Not all peptides have the same amount of research behind them, and evidence is only one part of responsible use. This scorecard shows how each measures up across the areas we think matter most: research strength, regulatory status, and whether we’ve evaluated a program offering it against our full Standard.

Evidence ratings reflect the directness and maturity of evidence for the specific use being evaluated. Evidence for a parent or related molecule is not automatically treated as evidence for the named peptide. These classifications are not FDA approval; PCAC recommendations are advisory, and the FDA has stated final determinations will follow completion of its review.

How We Arrived at These Ratings

BPC-157 — Tier 3: Investigational.

The FDA reviewed BPC-157 for ulcerative colitis. The biological rationale and preclinical literature move the indication beyond purely speculative biology, but the FDA concluded available information was insufficient to establish effectiveness and raised additional characterization and safety questions.

Standard interpretation: meaningful preclinical rationale, insufficient controlled human evidence. Tier 3.

KPV — Tier 4: Speculative for Gut Inflammation.

The FDA evaluated KPV for wound healing and inflammatory conditions and reported the nomination provided no human clinical evidence, with no clinical studies of human KPV administration identified for these uses. Preclinical inflammatory models create a plausible rationale but don’t establish clinical benefit.

Standard interpretation: direct preclinical evidence, no established human efficacy. Tier 4.

TB-500 — Tier 3: Investigational for Wound Healing.

The FDA evaluated TB-500 for wound healing and reported it did not identify information showing TB-500 administered to patients for a disease or condition. Much of the common rationale for TB-500 derives from research on full-length thymosin beta-4. This is biologically informative, but under the Standard, evidence for a parent molecule doesn’t transfer to a non-identical fragment.

Standard interpretation: substantial indirect rationale, sparse direct evidence for TB-500 itself. Tier 3 for the FDA-reviewed use.

MOTS-c — Tier 3: Investigational for Metabolic Health.

The FDA evaluated MOTS-c for obesity and osteoporosis and reported no publicly available clinical studies of MOTS-c administered to humans for these uses, despite direct mechanistic/preclinical research and human studies of endogenous MOTS-c physiology. The gap is administration: observing a naturally occurring peptide’s biology doesn’t establish that giving it exogenously produces a clinical benefit.

Standard interpretation: strong direct biological rationale with an important human-intervention gap. Tier 3.

Semax — Tier 3: Investigational.

The FDA evaluated Semax for cerebral ischemia, migraine, and trigeminal neuralgia. Unlike several peptides here, Semax has direct human literature, including small neurological-outcome studies, but the FDA concluded the evidence was insufficient to establish effectiveness for the reviewed conditions, citing small sample sizes and incomplete endpoints.

Standard interpretation: direct but limited, insufficiently validated human evidence. Tier 3.

Epitalon — Tier 4: Speculative for Insomnia and Longevity.

The FDA reviewed Epitalon for insomnia and reported available clinical information primarily addressed melatonin-related measures rather than clinical insomnia outcomes, with no studies identified evaluating the substance in insomnia patients via the proposed route. Additional observational studies on improved mortality outcomes are suggestive but inadequately designed.

Standard interpretation: indirect evidence without adequate direct clinical evidence for insomnia or longevity. Tier 4.

Emideltide / DSIP — Tier 3 for Chronic Insomnia, Tier 4 for Less-Supported Indications.

The FDA evaluated emideltide for opioid withdrawal, chronic insomnia, and narcolepsy. Direct human sleep studies exist for chronic insomnia, making it more than a purely mechanistic hypothesis, but the FDA characterized the evidence as preliminary and inconsistent, with no data supporting the nominated subcutaneous route. Emideltide was the only one of the seven PCAC-reviewed substances that did not receive a favorable recommendation.

Standard interpretation: Tier 3 for chronic insomnia; Tier 4 for other indications.

Sermorelin — Tier 2: Emerging for Muscle Mass and Sleep.

Sermorelin has a long clinical history, including prior FDA approval for diagnostic and pediatric growth-hormone-deficiency use, and a meaningful body of human research on the growth-hormone axis. Most of that evidence resides within a narrower population and indication than the broader adult longevity use for which it’s now commonly discussed, although a few small clinical studies exist.

Standard interpretation: substantive direct human evidence within its original indication; Emerging for the broader longevity uses now common in practice. Tier 2.

Available at AgelessRxSermorelin injectionExplore

GHK-Cu — Tier 2: Emerging for Skin Health.

GHK-Cu has a meaningful published record on skin remodeling, including mechanistic and preclinical evidence of effects on collagen synthesis, wound contraction, and tissue-repair signaling. Much of the human-relevant evidence base is older, smaller-scale, or industry-associated rather than independently replicated in large controlled trials, and a randomized, placebo-controlled human trial for topical wound healing is only now underway, meaning definitive controlled human efficacy data is still forthcoming rather than established. Broader “regenerative” claims extending past topical skin effects reach further than the current direct evidence supports and are firmly speculative (Tier 4).

Standard interpretation: strong mechanistic and preclinical evidence for topical skin effects, not yet at the volume or independence of replication needed for Established. Tier 2.

Available at AgelessRxGHK-Cu CreamExplore

PT-141 — Tier 1: Established, for Its Approved Indication Only.

Bremelanotide (Vyleesi) is FDA-approved for acquired, generalized hypoactive sexual desire disorder in premenopausal women, based on two Phase III RECONNECT trials in over 1,200 women. That approval is indication- and population-specific: the FDA label explicitly excludes postmenopausal women and men and does not cover use for enhancing sexual performance. Off-label use in men, a common real-world application, has not undergone the same regulatory review and should be assessed on its own evidence rather than inheriting this Tier 1 rating.

Available at AgelessRxPT-141 injectionExplore

What This Table Does Not Mean

These ratings don’t rank which peptide is “best.” A Tier 3 rating doesn’t mean a peptide should be prescribed, and a favorable regulatory recommendation doesn’t raise its Evidence Tier.

A Tier 4 rating doesn’t mean a peptide can never reach Tier 1 or Tier 2. As research evolves, especially if peptides are added to the 503A Bulks List, ratings can move with the evidence base. If a rigorous human study of BPC-157 for a specific use is published, that indication gets reassessed. The point of the rating isn’t to remove uncertainty, but to make the level of uncertainty visible.

What to Ask Before Starting Any Peptide

Discussion

The peptide market presents two opposing risks. One is dismissal: treating every investigational peptide as scientifically invalid because many claims exceed the evidence. The other is overstatement: treating biological plausibility, consumer experience, regulatory discussion, or a single lab result as proof of clinical benefit. Neither reflects the evidence well.

Some investigational peptides carry substantial mechanistic and preclinical research that warrants serious research efforts to validate their potential. Some have early human evidence, while others draw on research involving related molecules that is informative but cannot be transferred directly. BPC-157’s evidence base and TB-500’s reliance on full-length thymosin beta-4 research are both examples of this, discussed in Part III. Scientific uncertainty does not make responsible evaluation impossible, but it changes what responsible evaluation requires: when evidence is at an earlier stage, claims should be more precise, documentation more rigorous, and monitoring more deliberate.

Limitations

The regulatory landscape referenced here is evolving and may have changed by the time this is read. Direct human evidence remains limited for several peptides discussed. Existing analytical studies cannot establish failure rates across the entire peptide market. The 2026 consumer research-grade peptide analysis cited above is a preprint and has not completed peer review. This paper uses a narrative rather than a registered systematic-review method. The scoring instruments described in Part II have not undergone independent validation or inter-rater reliability testing, and several scoring thresholds are normative, subject to revision after pilot use. AgelessRx has a commercial interest in peptide care, a conflict that should stay visible when interpreting this Standard, including our own self-assessment.

Conclusion

The central challenge in this category is no longer simply whether these molecules can be accessed; it is whether the systems surrounding them can distinguish investigation from proof, regulatory discussion from approval, purity from complete analytical quality, provider involvement from accountable clinical care, and testimonials from outcomes research.

A responsible peptide program should demonstrate verifiable sourcing, fit-for-purpose analytical quality, accountable clinical governance, evidence-calibrated communication, meaningful patient transparency, and systematic outcomes accountability. This Standard should be applied to every organization operating in this category, including AgelessRx. Its success should be judged not by whether companies adopt its language, but by whether peptide quality becomes easier to verify and unsupported claims become harder to make.

Validation Agenda

The Standard is a proposed model, not a finished one. Validation should include independent expert review, pilot assessment, inter-rater reliability testing, construct validation, public comment, and scheduled revision, including independent grading exercises to test whether different reviewers assign the same Evidence Tier from the same evidence.

References

Authorship and Review